Collegium Pharmaceutical, Inc. (COLL) vs Evolus, Inc. (EOLS)
- Collegium Pharmaceutical, Inc. COLL 23.19 +0.04%
- Evolus, Inc. EOLS 7.10 −6.21%
Collegium Pharmaceutical, Inc. and Evolus, Inc. are both Drug Manufacturers Specialty & Generic companies. Collegium Pharmaceutical, Inc. is the larger, with a market value of $754.6M against $500.0M — 1.5× the size. Evolus, Inc. has negative trailing earnings, so its P/E is not meaningful; Collegium Pharmaceutical, Inc. trades at 15.2×. Collegium Pharmaceutical, Inc. grew revenue faster over the last twelve months: 14.3% against 13.9%. Collegium Pharmaceutical, Inc. has the higher net margin (5.93% vs −10.9%) and the higher return on invested capital (7.85% vs −14.5%). Across the 18 metrics below, Collegium Pharmaceutical, Inc. leads on 9 and Evolus, Inc. on 9.
Valuation
Profitability
| Metric | COLL | EOLS | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 60.02% | 66.74% | 53.94% |
| Operating margin | 19.48% | (5.90%) | 0.00% |
| Net margin | 5.93% | (10.85%) | 0.00% |
| Free cash flow margin | 40.62% | (6.92%) | 0.00% |
| Return on equity | 17.61% | 138.57% | (0.40%) |
| Return on assets | 2.57% | (14.40%) | (3.32%) |
| Return on invested capital | 7.85% | (14.47%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack